Employers › Inhibrx Biosciences
Recordkeeping fees per participant · Inhibrx Biosciences, Inc 401(k) Plan · plan year 2024
$106.61
Higher than 60% of the 14,075 plans $10 to 50M that report it.
= $21,748 / 204
Schedule H, line 2i(3); OTH_RECORDKEEPING_FEES_AMT pos 160; filing 20251009162603NAL0016098962001, received 2025-10-09
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20251009162603NAL0016098962001, received 2025-10-09
Percentiles compare this plan with the Schedule H plans $10 to 50M in assets of the same plan year, excluding final filings; shown only where at least 50 comparable plans report the figure. Plan year 2024-01-01 to 2024-12-31, filing received 2025-10-09.
Administrative expenses excluding investment management, per participant
$106.61
Higher than 45% of the 24,371 plans $10 to 50M that report it.
= $21,748 / 204
derived, admin_expenses (2i(12)) minus invst_mgmt_fees (2i(5)), floored at 0; filing 20251009162603NAL0016098962001, received 2025-10-09
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20251009162603NAL0016098962001, received 2025-10-09
Administrative expenses per participant
$106.61
Higher than 28% of the 25,098 plans $10 to 50M that report it.
= $21,748 / 204
Schedule H, line 2i(12) total administrative expenses; TOT_ADMIN_EXPENSES_AMT pos 109; filing 20251009162603NAL0016098962001, received 2025-10-09
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20251009162603NAL0016098962001, received 2025-10-09
Administrative expenses as a share of assets
0.110%
Higher than 22% of the 25,132 plans $10 to 50M that report it.
= $21,748 / $19,690,410
Schedule H, line 2i(12) total administrative expenses; TOT_ADMIN_EXPENSES_AMT pos 109; filing 20251009162603NAL0016098962001, received 2025-10-09
assets_eoy: Schedule H, Part I line 1f col (b); TOT_ASSETS_EOY_AMT pos 61; filing 20251009162603NAL0016098962001, received 2025-10-09
Employer contributions per participant
$7,330
Higher than 97% of the 24,050 plans $10 to 50M that report it.
= $1,495,237 / 204
Schedule H, Part II line 2a(1)(A); EMPLR_CONTRIB_INCOME_AMT pos 68; filing 20251009162603NAL0016098962001, received 2025-10-09
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20251009162603NAL0016098962001, received 2025-10-09
Employer share of total contributions
33.0%
Higher than 69% of the 24,084 plans $10 to 50M that report it.
= $1,495,237 / $4,531,061
Schedule H, Part II line 2a(1)(A); EMPLR_CONTRIB_INCOME_AMT pos 68; filing 20251009162603NAL0016098962001, received 2025-10-09
total_contrib: Schedule H, line 2a(3); TOT_CONTRIB_AMT pos 72; filing 20251009162603NAL0016098962001, received 2025-10-09
Plan terms are described in Inhibrx Biosciences, Inc.'s SEC filings: Form 10-K filed 2026-03-19. No term could be quoted from them with the required precision.
2E profit-sharing · 2G fully participant-directed · 2J 401(k) feature · 2K 401(m) arrangement · 2F ERISA 404(c) plan · 2T default investment (QDIA) · 3D IRS pre-approved plan · Form 5500, line 8a; TYPE_PENSION_BNFT_CODE pos 81; filing 20251009162603NAL0016098962001, received 2025-10-09
| Field | Value | Source |
|---|---|---|
| Plan sponsor | INHIBRX BIOSCIENCES, INC. | Form 5500, Part II line 2a; SPONSOR_DFE_NAME pos 19; filing 20251009162603NAL0016098962001, received 2025-10-09 |
| Plan name | INHIBRX BIOSCIENCES, INC 401(K) PLAN | Form 5500, line 1a; PLAN_NAME pos 16; filing 20251009162603NAL0016098962001, received 2025-10-09 |
| Sponsor EIN / plan number | 99-0613523 / 001 | Form 5500, line 2b; SPONS_DFE_EIN pos 44; filing 20251009162603NAL0016098962001, received 2025-10-09 |
| Plan type | single-employer | Form 5500, Part I line A; TYPE_PLAN_ENTITY_CD pos 4; filing 20251009162603NAL0016098962001, received 2025-10-09 |
| Sponsor location | SAN DIEGO, CA | Form 5500, line 2a; SPONS_DFE_MAIL_US_STATE pos 25; filing 20251009162603NAL0016098962001, received 2025-10-09 |
| Industry (business code) | 325410, Manufacturing | Form 5500, line 2d; BUSINESS_CODE pos 46; filing 20251009162603NAL0016098962001, received 2025-10-09 |
| Plan year | 2024-01-01 to 2024-12-31 | Form 5500, Part I plan year; FORM_PLAN_YEAR_BEGIN_DATE pos 2; filing 20251009162603NAL0016098962001, received 2025-10-09 |
| Filing received | 2025-10-09 | Form 5500, EFAST2 receipt date; DATE_RECEIVED pos 102; filing 20251009162603NAL0016098962001, received 2025-10-09 |
| Final filing | no | Form 5500, Part I line B; FINAL_FILING_IND pos 8; filing 20251009162603NAL0016098962001, received 2025-10-09 |
| Amended filing | no | Form 5500, Part I line B; AMENDED_IND pos 7; filing 20251009162603NAL0016098962001, received 2025-10-09 |
| Participants, beginning of year | 191 | Form 5500, line 5; TOT_PARTCP_BOY_CNT pos 71; filing 20251009162603NAL0016098962001, received 2025-10-09 |
| Active participants | 159 | Form 5500, line 6a(2); TOT_ACTIVE_PARTCP_CNT pos 72; filing 20251009162603NAL0016098962001, received 2025-10-09 |
| Participants, end of year | 209 | Form 5500, line 6f; TOT_ACT_RTD_SEP_BENEF_CNT pos 77; filing 20251009162603NAL0016098962001, received 2025-10-09 |
| Participants with an account balance | 204 | Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20251009162603NAL0016098962001, received 2025-10-09 |
| Total assets, beginning of year | $13,830,236 | Schedule H, Part I line 1f col (a); TOT_ASSETS_BOY_AMT pos 30; filing 20251009162603NAL0016098962001, received 2025-10-09 |
| Total assets, end of year | $19,690,410 | Schedule H, Part I line 1f col (b); TOT_ASSETS_EOY_AMT pos 61; filing 20251009162603NAL0016098962001, received 2025-10-09 |
| Net assets, end of year | $19,690,410 | Schedule H, line 1l col (b); NET_ASSETS_EOY_AMT pos 67; filing 20251009162603NAL0016098962001, received 2025-10-09 |
| Total income | $7,203,115 | Schedule H, Part II line 2d; TOT_INCOME_AMT pos 97; filing 20251009162603NAL0016098962001, received 2025-10-09 |
| Net income | $5,860,174 | Schedule H, line 2k; NET_INCOME_AMT pos 111; filing 20251009162603NAL0016098962001, received 2025-10-09 |
| Employer contributions | $1,495,237 | Schedule H, Part II line 2a(1)(A); EMPLR_CONTRIB_INCOME_AMT pos 68; filing 20251009162603NAL0016098962001, received 2025-10-09 |
| Participant contributions | $2,762,960 | Schedule H, line 2a(1)(B); PARTICIPANT_CONTRIB_AMT pos 69; filing 20251009162603NAL0016098962001, received 2025-10-09 |
| Other contributions (incl. rollovers) | $272,864 | Schedule H, line 2a(1)(C); OTH_CONTRIB_RCVD_AMT pos 70; filing 20251009162603NAL0016098962001, received 2025-10-09 |
| Total contributions | $4,531,061 | Schedule H, line 2a(3); TOT_CONTRIB_AMT pos 72; filing 20251009162603NAL0016098962001, received 2025-10-09 |
| Benefit payments | $1,315,350 | Schedule H, line 2e(4); TOT_DISTRIB_BNFT_AMT pos 101; filing 20251009162603NAL0016098962001, received 2025-10-09 |
| Total expenses (incl. benefit payments) | $1,342,941 | Schedule H, line 2j; TOT_EXPENSES_AMT pos 110; filing 20251009162603NAL0016098962001, received 2025-10-09 |
| Total administrative expenses | $21,748 | Schedule H, line 2i(12) total administrative expenses; TOT_ADMIN_EXPENSES_AMT pos 109; filing 20251009162603NAL0016098962001, received 2025-10-09 |
| Contract administrator fees | $0 | Schedule H, line 2i(2); CONTRACT_ADMIN_FEES_AMT pos 106; filing 20251009162603NAL0016098962001, received 2025-10-09 |
| Recordkeeping fees | $21,748 | Schedule H, line 2i(3); OTH_RECORDKEEPING_FEES_AMT pos 160; filing 20251009162603NAL0016098962001, received 2025-10-09 |
| IQPA audit fees | $0 | Schedule H, line 2i(4); IQPA_AUDIT_FEES_AMT pos 161; filing 20251009162603NAL0016098962001, received 2025-10-09 |
| Investment advisory and management fees | $0 | Schedule H, line 2i(5); INVST_MGMT_FEES_AMT pos 107; filing 20251009162603NAL0016098962001, received 2025-10-09 |
| Administrative expenses excluding investment management | $21,748 | derived, admin_expenses (2i(12)) minus invst_mgmt_fees (2i(5)), floored at 0; filing 20251009162603NAL0016098962001, received 2025-10-09 |
| Held in master trusts | $0 | Schedule H, line 1c(11) col (b); INT_MASTER_TR_EOY_AMT pos 53; filing 20251009162603NAL0016098962001, received 2025-10-09 |
| Held in common/collective trusts | $211,232 | Schedule H, line 1c(9) col (b); INT_COMMON_TR_EOY_AMT pos 51; filing 20251009162603NAL0016098962001, received 2025-10-09 |
| Held in mutual funds | $19,101,361 | Schedule H, line 1c(13) col (b); INT_REG_INVST_CO_EOY_AMT pos 55; filing 20251009162603NAL0016098962001, received 2025-10-09 |
| Independent auditor | CBIZ CPAS P.C. | Schedule H, Part III line 3a; ACCOUNTANT_FIRM_NAME pos 116; filing 20251009162603NAL0016098962001, received 2025-10-09 |
Position = column in the DOL layout for form year 2024. Filing 20251009162603NAL0016098962001, received 2025-10-09.
| Provider | Relationship | Service codes | Direct compensation | Indirect |
|---|---|---|---|---|
| FIDELITY INVESTMENTS INSTITUTIONALrecordkeeper | RECORDKEEPER | 37 Participant loan processing; 64 Recordkeeping fees; 65 Account maintenance fees | $21,748 | yes |
Schedule C Part I line 2: name (a), service codes (b), relationship (c), direct compensation paid by the plan (d), indirect compensation received (e). Filing 20251009162603NAL0016098962001, received 2025-10-09.
No filing for the previous plan year is in the data, so there is no year-over-year comparison.
Sponsor name as filed: INHIBRX BIOSCIENCES, INC.; SEC registrant: Inhibrx Biosciences, Inc. (CIK 2007919, matched by EIN; display name from the Form 10-K cover).